Gunes Muhammed, Cekic Sukru, Kilic Sara Sebnem
Departments of Pediatric Immunology-Rheumatology, Uludag University Faculty of Medicine, Görükle, Bursa, Turkey.
Pediatr Int. 2017 Jun;59(6):655-660. doi: 10.1111/ped.13265. Epub 2017 Apr 24.
Periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis (PFAPA) syndrome is the most frequent repetitive fever syndrome in childhood. It is characterized by fever episodes lasting for approximately 3-6 days, once every 3-8 weeks.
Clinical and laboratory data for PFAPA syndrome patients between January 2010 and December 2014 followed up at a tertiary pediatric care hospital were reviewed.
Four hundred children (256 male, 144 female; mean age at diagnosis, 4.2 ± 2.2 years), were enrolled in the study. During the episodes, mean leukocyte number was high (12 725/mm ) with predominant neutrophils. The mean number of monocytes was 1256/mm , and 90.2% had monocytosis. Serum amyloid A and C-reactive protein were high in 84.6% and in 77.8% of the patients, respectively. Mediterranean fever (MEFV) gene heterozygous mutation was identified in 57 of the 231 patients (24.7%) in whom genetic analysis had been performed. The most frequent mutation was heterozygous M694V (10%, n = 23). Extension of between-episode interval following prophylaxis was noted in 85% of those on regular colchicine treatment (n = 303). In the colchicine group, between-episode interval was prolonged from 18.8 ± 7.9 days (before colchicine treatment) to 49.5 ± 17.6 days on prophylactic colchicine therapy; also, prophylactic treatment was more effective in reducing episode frequency in patients with MEFV gene variant (n = 54, 96%) than in those without (n = 122, 80%; P = 0.003).
This study has involved the largest number of PFAPA syndrome patients in the literature. It is particularly important to assess and to demonstrate the high rate of response to colchicine prophylaxis in PFAPA syndrome patients, especially those with MEFV variant. On blood screening, neutrophilia associated with monocytosis and low procalcitonin could contribute to diagnosis.
周期性发热、口疮性口炎、咽炎和颈淋巴结炎(PFAPA)综合征是儿童期最常见的反复发热综合征。其特征为发热发作持续约3 - 6天,每3 - 8周发作一次。
回顾了2010年1月至2014年12月在一家三级儿科护理医院接受随访的PFAPA综合征患者的临床和实验室数据。
400名儿童(男256名,女144名;诊断时平均年龄4.2±2.2岁)纳入研究。发作期间,平均白细胞计数较高(12725/mm³),以中性粒细胞为主。单核细胞平均计数为1256/mm³,90.2%的患者有单核细胞增多。84.6%的患者血清淀粉样蛋白A升高,77.8%的患者C反应蛋白升高。在进行基因分析的231名患者中,57名(24.7%)检测到地中海热(MEFV)基因杂合突变。最常见的突变是杂合M694V(10%,n = 23)。85%接受常规秋水仙碱治疗的患者(n = 303)在预防后发作间期延长。在秋水仙碱组,发作间期从秋水仙碱治疗前的18.8±7.9天延长至预防性秋水仙碱治疗时的49.5±17.6天;此外,预防性治疗对MEFV基因变异患者(n = 54,96%)降低发作频率的效果比对无该变异患者(n = 122,80%;P = 0.003)更有效。
本研究纳入了文献中数量最多的PFAPA综合征患者。评估并证明PFAPA综合征患者,尤其是有MEFV变异的患者对秋水仙碱预防的高反应率尤为重要。血液筛查时,与单核细胞增多和降钙素原降低相关的中性粒细胞增多有助于诊断。